In 2018, Teva introduced DuoResp® Spiromax® (budesonide / formoterol), a dry powdered inhaler device for treating asthma and COPD. Since then, DuoResp® Spiromax® has been used by thousands of Australians.
Asthma: DuoResp Spiromax is indicated 1 for asthma in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk and exacerbations. Dose and method: DuoResp Spiromax can be used according to different treatment approaches: A. Anti-inflammatory reliever therapy (patients with mild disease). B. Anti-inflammatory reliever plus maintenance therapy. C. Maintenance therapy (fixed dose). (The 400/12 strength should not be used for the anti-inflammatory reliever plus maintenance therapy regimen).
COPD*: DuoResp Spiromax is indicated for the symptomatic treatment of moderate to severe COPD (FEV1 ≤50% predicted normal) in adults with frequent symptoms despite long-acting 2 DuoResp bronchodilator use, and/or a history of recurrent exacerbations. DuoResp Spiromax is not indicated for the initiation of bronchodilator therapy in COPD.
Back to contents.
Australian Product Information, DuoResp Spiromax 200/6 & 400/12 V5.0.